Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL1 CAR-T in Relapsed and Refractory Acute Myeloid Leukemia
NCT05467202Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB-012 in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Evaluation of Safety at 2 years and Changes in cytokine level at 2 years. Status: unknown.
02
Drugs
CB-012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05467202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467202.